Pharma BD Deal Intelligence
Not an acquisition: Roche never bought Halozyme (still independent, NASDAQ: HALO); this was an ENHANZE tech-licensing deal that successfully delivered Phesgo, a genuine Roche growth driver
Full analysis, sources & comparables →Form 8-K exhibit documents the expanded ENHANZE collaboration and license agreement with Roche, including the new target license, upfront payment, milestone…
Halozyme inks $2B+ in ENHANZE licensing deals with BMS and Roche; Roche's extension underscores growing demand for subcutaneous reformulation of biologics.
ENHANZE is now used in 10+ commercial co-administered products in 100+ countries with tens of billions of dollars in commercial revenue across Roche, J&J,…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Roche expanded its longstanding ENHANZE collaboration with Halozyme to add an additional undisclosed therapeutic target. Halozyme received $30M upfront plus eligibility for up to $160M in development, regulatory and sales-based milestones plus tiered royalties. The expansion built on the original 2006 collaboration that produced subcutaneous Herceptin and MabThera/Rituxan formulations.
Not an acquisition: Roche never bought Halozyme (still independent, NASDAQ: HALO); this was an ENHANZE tech-licensing deal that successfully delivered Phesgo, a genuine Roche growth driver
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Halozyme Therapeutics, Inc. (this deal) | 2017 | $190M | 75 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2017 deals · Roche Holding AG deals · Multiple (undisclosed) deals